To provide long term capital growth.
Name | % Net Assets |
---|---|
BP | 7.8% |
GlaxoSmithKline | 5.1% |
Royal Dutch Shell A | 4.8% |
Royal Dutch Shell B | 3.7% |
HSBC Holdings PLC (UK Reg) | 3.6% |
Astrazeneca | 3.6% |
Vodafone group | 2.8% |
BHP BILLITON | 2.7% |
Barclays | 2.2% |
Standard Chartered | 1.9% |
Key | % Net Assets |
---|---|
BP | 7.8% |
GlaxoSmithKline | 5.1% |
Royal Dutch Shell A | 4.8% |
Royal Dutch Shell B | 3.7% |
Other | 78.6% |
Date | n/a |
---|---|
Bid | 0.00 |
Offer | 0.00 |
Currency | n/a |
Change | 0.00 |
% | n/a |
YTD change | 0.00 |
YTD % | n/a |
Fund Inception | 06/03/2006 |
---|---|
Fund Manager | Michael Barakos |
TER | - |
Minimum Investment | |
---|---|
Initial | n/a |
Additional | n/a |
Savings | n/a |
Charges | |
---|---|
Initial | n/a |
Annual Mang't | 0.90% |
Exit | n/a |
Name | % |
---|---|
Standard deviation | 0.02 |
Sharpe ratio | 0.11 |
You are here: research